摘要
目的:观察司美格鲁肽对原发性高血压合并肥胖及2型糖尿病(T2DM)的治疗效果,及对体质量和血压的影响。方法:选取2022年2月于北京安贞医院就诊的107例肥胖及原发性高血压的T2DM患者为研究对象。随机分为对照组(n=54)及观察组(n=53),对照组继续降糖方案,观察组在原治疗基础上加用司美格鲁肽治疗,每4周门诊随访,随访12周,观察两组血糖、胰岛素抵抗、胰岛β细胞功能、血压和BMI的变化。结果:两组患者治疗前FPG、HbA1C、C肽、胰岛素抵抗指数(HOMA-IR)、HOMA-β均无明显差异(P>0.05)。治疗后,对照组上述指标较治疗前均无明显差异;观察组FPG、HbA1C明显低于治疗前及对照组治疗后(P<0.05),HOMA-IR有降低趋势,而C肽、HOMA-β有增高趋势(P>0.05)。对照组治疗前后SBP、DBP及BMI均无明显改变(P>0.05),观察组12周的SBP和BMI明显低于治疗前及对照组(P<0.05)。结论:司美格鲁肽用于原发性高血压合并肥胖及T2DM患者,显著改善血糖、血压,并降低体质量。
Objective:To observe the clinical effect of semaglutide on type 2 diabetes mellitus with obesity and primary hypertension,and the influence on weight and blood pressure.Methods:A total of 107 patients with type 2 diabetes complicated with obesity and primary hypertension who admitted to Anzhen Hospital from February 1st,2022 to February 28th,2022 were selected as the research subjects.They were randomly divided into control group(n=54)and observation group(n=53).The control group was maintained with the original treatment,and the observation group was treated with semaglutide on the basis of original treatment.Within 12 weeks,the patients were followed up every 4 weeks to observe the changes of blood glucose index,islet function index,blood pressure and BMI.Result:Before treatment,there were no significant differences in FPG,HbA1c,C-peptide,HOMA-IR and HOMA-βbetween two groups(P>0.05).After treatment,there were no significant differences in the above indicators in control group.In observation group,FPG and HbA1c were significantly lower than these indexes before treatment,also lower than these indexes of control group after treatment(P<0.05).In observation group,HOMA-IR was lower than that before treatment,C-peptide and HOMA-βwere higher than these before treatment(P>0.05).SBP,DBP and BMI of the control group did not change significantly during the follow-up period(P>0.05),while at the end of follow up,SBP and BMI of the observation group were significantly lower than those before treatment,and significantly lower than those of control group(P<0.05).Conclusions:Long-term use of semaglutide has the effect of lowering blood pressure,lowering blood sugar and reducing weight for type 2 diabetes mellitus patients with obesity and primary hypertension.
作者
张凤丽
赵一楠
李宇
文丽娜
陶红
ZHANG Fengli;ZHAO Yinan;LI Yu;WEN Lina;TAO Hong(Department of Endocrinology,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart,Lung and Blood Vessel Diseases,Beijing 100029,China)
出处
《心肺血管病杂志》
CAS
2023年第1期27-30,36,共5页
Journal of Cardiovascular and Pulmonary Diseases
关键词
2型糖尿病
司美格鲁肽
肥胖
原发性高血压
Type 2 diabetes mellitus
Semaglutide
Obesity
Primary hypertension
